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Abstract
 
We have examined the expression of caveolin in
MDCK cells under conditions that vary cellular cholesterol
concentration. Caveolin mRNA levels dropped to one-sixth
of control levels after treatment with simvastatin, an inhibitor
of cholesterol synthesis, or 
 
b
 
-trimethyl cyclodextrin (CD), a
cholesterol sequestering drug. Both simvastatin and CD
treatment decreased total cellular cholesterol levels to about
50% of control values. The potent activator of the sterol regula-
tory element, 25-hydroxycholesterol, showed no direct regula-
tion of caveolin mRNA levels. Caveolin protein concentration
was also decreased to 50% of control values in cholesterol-
depleted cells, giving rise to a severe attenuation of caveolin
expression detected by indirect immunofluorescence label-
ing. Quantitative electron microscopy showed a total loss of
morphologically recognizable invaginated caveolae after these
cholesterol depletion treatments. When the number of invag-
inated caveolae per cell was expressed as a function of the cel-
lular cholesterol content, a threshold phenomenon was ob-
served, suggesting that caveolae only form when the steady
state cellular cholesterol is above 50% of control values.
These findings indicate that caveolins, and caveolae, may play
an important part in cellular cholesterol homeostasis.—
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Caveolae are distinctive, flask-shaped invaginations
of the plasma membrane found in many cells. They
have a characteristic lipid composition, rich in choles-
terol and gangliosides (1–3), and are associated with
the presence of a 22 kD protein called caveolin. Caveo-
lin has an unusual membrane topography with both
the amino and carboxy terminus exposed to the cyto-
plasmic face of the caveolar membrane, and a long hy-
drophobic segment of 33 amino acids (4). In addition,
it is palmitoylated on cysteine residues in the C-terminal
domain of the protein (5, 6). Four isoforms of caveolin
have been described: caveolin-1
 
a
 
 and 1
 
b
 
 are differen-
 
tially spliced from a single gene (7); caveolin-2 is the
product of a second gene that is often found expressed
in the same cells as caveolin-1 (8); and caveolin-3 is en-
coded by a third gene that is predominantly expressed
in muscle tissue (9, 10). Most cells contain one or more
types of caveolin, and in those cells where caveolin has
not been found it is possible that additional caveolin
isoforms exist.
A close and interdependent relationship between
cholesterol and caveolin has been observed for the for-
mation of stable caveolae. Thus it has been shown that
lymphocytes, which do not express any known isoform
of caveolin, do not have morphologically recognizable
caveolae (11). However, transfection of caveolin-1 causes
de novo formation of caveolae (12). On the other hand,
when fibroblasts were treated with the cholesterol-binding
drug, filipin, the caveolae collapsed into the plasma
membrane, suggesting a requirement for cholesterol to
maintain the morphology of caveolae (13). A possible
explanation for a need for both caveolin and cholesterol
in the formation of invaginated caveolae is that caveo-
lin is itself a cholesterol-binding protein (14). The pres-
ence of cholesterol promotes oligomerization of the
protein (14–17) and these oligomers are likely to con-
tribute to the striated coat seen around caveolae in
electron micrographs (15).
Caveolin is also found in the 
 
trans
 
 Golgi network
(TGN) of fibroblasts by immunofluorescence (4) and
has been described as a component of apical and baso-
lateral transport vesicles in Madin-Darby canine kidney
(MDCK) cells (18). Furthermore, it has been reported
 
Abbreviations: CD, 
 
b
 
-trimethyl cyclodextrin; HMG-CoA, 3-hydroxy-
3-methylglutaryl coenzyme A; MDCK, Madin-Darby canine kidney
cells; 25-OHC, 25-hydroxycholesterol; SREBP, sterol regulatory ele-
ment binding protein.
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that the intracellular distribution of caveolin can be ex-
perimentally manipulated in some cells by enzymatic
oxidation of surface cholesterol (19) or by depolymer-
ization of microtubules (20). These studies suggest that
caveolin location is also dynamic within the cell and
might have a role in cholesterol transport.
The function of caveolae is not known, although
roles in the uptake of small solutes (13), transcytosis of
lipoprotein particles across endothelial cells (21), and
signal transduction (22, 23) have been proposed (24).
In addition, it has been reported that exchange of cho-
lesterol from exogenous low density lipoprotein (LDL)
particles to fibroblasts results in selective transfer to cav-
eolae (25). Newly synthesized cholesterol was also selec-
tively removed from a caveolae fraction when [
 
3
 
H] me-
valonate-labeled fibroblasts were incubated in plasma
(25). Thus, understanding the mechanisms controlling
the formation of caveolae might be of considerable im-
portance in the reversal of atherosclerosis. In this pa-
per we describe the control of caveolin expression by
the level of endogenous cholesterol and a threshold ef-
fect of cellular cholesterol on the number of caveolae
found per cell.
MATERIALS AND METHODS
 
Cell culture
 
Type II MDCK cells were routinely grown in com-
plete Dulbecco’s modified Eagle’s medium (DMEM) 
 
1
 
10% fetal calf serum supplemented with 
 
l
 
-gluta-
mine, penicillin, and streptomycin) in T75 flasks and
were certified free of 
 
Mycoplasma
 
 contamination. Cells
were passaged every 3 to 4 days at confluence, with
feeding every 2 days. For cholesterol depletion experi-
ments, confluent monolayers were first changed to ap-
propriate media (complete DMEM (CM)), as above
except with 10% human serum or lipoprotein-defi-
cient serum (LPDS)-DMEM containing 10% lipopro-
tein-depleted human serum (26) with other additions
as indicated. In all cases, parallel cultures were tested
for cell viability by trypan blue exclusion and shown to
be over 95%.
 
Preparation of RNA
 
Cells were seeded into 60-mm dishes for experiments
where a preparation of total RNA was sufficient. A sin-
gle dish was used for each condition, and all experi-
ments were performed on at least three separate occa-
sions. Results were the same in all cases. Total RNA was
prepared using a modification of the guanidinium
isothiocyanate method (27). Briefly, cells were washed
twice in PBS and then lysed directly into denaturing so-
lution containing guanidinium thiocyanate. This lysate
was acidified with sodium acetate, extracted with acidi-
fied phenol and then chloroform and isoamyl alcohol,
microfuged, and then total RNA was precipitated from
isopropanol. The resulting pellet was resuspended
in guanidinium thiocyanate and reprecipitated from
isopropanol. The final pellet contained between 20
and 60 
 
m
 
g of total RNA, depending on the experimen-
tal condition.
 
Northern blotting and hybridization
 
Northern blots and hybridizations were performed
essentially as described (28). Briefly, RNA was electro-
phoresed on (formaldehyde-free) 1% agarose gels with
1 
 
3
 
 MOPS running buffer. Samples were loaded in 1 
 
3
 
MOPS, 50% deionized formamide, 6% formaldehyde,
and 5% glycerol. After electrophoresis, the gel was
stained with ethidium bromide (presence of 28S, 18S
and 5S ribosomal RNA (rRNA) bands indicating intact
RNA) and then transferred to Hybond-N
 
1 
 
under vac-
uum, using alkaline conditions.
Caveolin blots were prehybridized for 4–24 h at 65
 
8
 
C,
and then hybridized overnight at 65
 
8
 
C to the probe at 2 
 
3
 
10
 
6
 
 cpm per ml of hybridization buffer. Prehybridiza-
tion and hybridization buffers were the same (4 
 
3
 
 SSC
(where 1 
 
3
 
 SSC is 0.15 
 
m
 
 NaCl and 0.015 
 
m
 
 sodium cit-
rate), 5 
 
3
 
 Denhardt’s solution and 50 m
 
m
 
 sodium
phosphate, pH 7.0) except that hybridization buffer
also contained 10% dextran sulfate. Blots were then
washed twice in 0.5 
 
3
 
 SSC, 0.1% SDS for 30 min at
65
 
8
 
C and then once in 0.2 
 
3
 
 SSC, 0.1% SDS for 30 min
at 65
 
8
 
C. Washed blots were then exposed to a phosphor-
imager plate and read on a Fuji/Berthold 1500 phos-
phorimage analyzer.
Subsequently, total RNA blots were hybridized to a
30-mer oligonucleotide complimentary to the 18S rRNA
to correct for loading and transfer errors. These hybri-
dizations were performed in essentially the same man-
ner, except that the hybridization was performed at
55
 
8
 
C and washes were performed in 4 
 
3
 
 SSC, 0.1% SDS
twice at room temperature and then once at 55
 
8
 
C. In
addition, an excess of unlabeled 18S oligonucleotide
was always added to the hybridization reaction to en-
sure that the probe was not limiting.
The probe for caveolin was a 670 bp 
 
Eco
 
RI-
 
Hpa
 
I frag-
ment of the MDCK caveolin cDNA, originally described
as VIP21 (18) but found to be identical to caveolin
(29), which was primed with an antisense oligonucle-
otide corresponding to bp 610–635. It was labeled us-
ing the Pharmacia Ready-to-go kit, and was routinely la-
beled to a specific activity of better than 10
 
9
 
 dpm per
 
m
 
g DNA.
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Measurement of endogenous cholesterol concentration
 
Cellular cholesterol concentrations were measured
by high performance liquid chromatography (HPLC)
(30). Cells were seeded in quadruplicate for each ex-
periment (generally performed on at least three sepa-
rate occasions) and media were supplied as appropri-
ate. At the conclusion of each experiment, cells were
washed twice in PBS and then lysed in 200 m
 
m
 
 sodium
hydroxide. An aliquot of each sample was retained for
protein estimation, the remainder was extracted into
methanol and hexane (in the presence of the antioxi-
dants: 20 
 
m
 
m
 
 butyl hydroxytoluene and 20 m
 
m
 
 EDTA).
The hexane fraction was then evaporated, resuspended,
and the cholesterol was analyzed on a reverse phase
C18 column with detection at 210 nm.
 
Electron microscopy
 
Cells were rinsed twice in PBS containing 0.1 m
 
m
 
CaCl
 
2
 
 and 1 m
 
m
 
 MgCl
 
2
 
 at room temperature and then
fixed in 2 ml of 2.5% glutaraldehyde in 50 m
 
m
 
 cacody-
late buffer, pH 7.35, containing 70 m
 
m
 
 KCl, 1.2 m
 
m
 
CaCl
 
2
 
, and 1.2 m
 
m
 
 MgCl
 
2
 
. After 1 h at room tempera-
ture, the cells were washed 4 times in 100 m
 
m
 
 cacody-
late buffer, pH 7.35, and then processed for epon em-
bedding after removing the cells from the dishes using
propylene oxide (31). After embedding and curing, 50-
to 60-nm sections were prepared and counterstained
with uranyl acetate and lead citrate. Sections were
viewed in a Jeol 1010 electron microscope. The num-
ber of surface caveolae was quantitated in a blind fash-
ion using a code that was only decoded after the com-
pletion of the analysis. Caveolae were defined as
uncoated 55–65 nm surface invaginations clearly con-
nected to the plasma membrane. Through necessity
this definition excluded any caveolae connected to the
cell surface by a neck that was not visible in the plane of
section. The number of invaginated caveolae was esti-
mated by counting the number of caveolar profiles per
cell profile and over 50 cells were analyzed for each ex-
periment. Results were confirmed in two independently
processed cell cultures.
 
Immunofluorescence labeling
 
Cells were fixed and stained as described by Bos,
Wraight, and Stanley (32) except that methanol–
acetone 1:1 was used as fixative at 
 
2
 
20
 
8
 
C for 10 min
and 5% FCS in PBS was used as quench buffer. The ca-
veolin polyclonal antiserum was purchased from Trans-
duction Laboratories.
 
Western Blot
 
Cells were washed 3 
 
3
 
 in PBS and then solubilized in
1 ml of 2% SDS. Proteins were separated on 12% poly-
acrylamide gels and then transferred to nitrocellulose
paper. The caveolin was detected by Western blot using
a 1:1000 dilution of polyclonal primary antibody
(Transduction Laboratories) and 
 
125
 
I-labeled protein
A. After 60 min incubation in the 
 
125
 
I-labeled protein A
(0.1 
 
m
 
Ci/ml), the filters were washed 3 
 
3
 
 in PBS con-
taining 0.02% Tween 20 and dried milk quenching pro-
tein, followed by one wash in PBS. The filters were then
dried and quantitated in a phosphorimager. In some
gels equal protein (80 
 
m
 
g) was loaded onto each lane.
Alternatively, equal volumes were added and caveolin
was related to the original protein concentration or cell
density. Protein content was measured by the bicincho-
ninic acid method.
RESULTS
Caveolin-1, originally termed VIP-21, has been cloned
from MDCK cells (18) where it has been shown to be
present in surface caveolae and associated with trans-
port vesicles leaving the 
 
trans
 
 Golgi network (4). We
therefore used this well-characterized cell system to exa-
mine the regulation of caveolin expression by cholesterol.
Type II MDCK cells were grown in normal culture
media containing 10% FCS until they reached conflu-
ence. The medium was then changed to DMEM con-
taining 10% human serum with various additions, and
the cells were grown for a further 3 days before extrac-
tion of lipids and cholesterol analysis by HPLC. In con-
trol cells, between 10 and 15 
 
m
 
g of cholesterol was de-
tected per mg cell protein, with a mean 
 
5
 
 13 
 
6
 
 0.77
(SE) 
 
m
 
g/mg (n 
 
5
 
 8). In order to deplete cells of en-
dogenous cholesterol, we incubated them for 3 days in
LPDS-DMEM with the addition of either 25 
 
m
 
m
 
 simva-
statin (an HMG-CoA reductase inhibitor; 
 
Fig. 1A
 
, col-
umn 3), or overnight in LPDS-DMEM containing 1
mg/ml of 
 
b
 
-trimethyl cyclodextrin (CD; Fig. 1A, col-
umn 5). Both treatments lowered the cellular choles-
terol to between 40 and 65% of control levels, with
slight variations between experiments. Treatment for
longer periods of time with CD caused the cells to de-
tach from the tissue culture dish: however, after all the
treatments in Fig. 1, cell viability measured by trypan
blue exclusion remained above 95%.
In a parallel experiment, the caveolin mRNA con-
centration was quantitated by Northern blot of total
RNA using a caveolin 1 cDNA probe (Fig. 1, panel B).
A single hybridizing band was found at approximately
2.3 kb, running in between the positions of 18S and
23S rRNA, consistent with the observation of Scherer et
al. (8). Loading of RNA was determined by hybridiza-
tion of the same blot with an 18S rRNA probe after
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waiting for the caveolin signal to decay (Fig. 1, panel
C). Both Northern blots were quantitated on a phos-
phorimage analyzer and the ratio of caveolin:18S rRNA
was taken as a measure of the level of expression of ca-
veolin mRNA per cell (Fig. 1, panel D). It can be seen
in Fig. 1D that the steady state level of caveolin mRNA
decreased significantly as the cellular cholesterol was
lowered. In the CD-treated cells (Fig. 1D, column 5),
caveolin message was 6-fold decreased relative to cells
grown in medium containing 10% human serum (Fig.
1D, column 1). This effect was not due to the CD itself,
as a decrease of expression was also observed in LPDS
medium containing simvastatin (Fig. 1D, column 3).
Furthermore, when the CD was added to complete me-
dium rather than LPDS medium, the cellular cholesterol
was reduced to a lesser extent (Fig. 1A, column 4 com-
pared with column 5) and the attenuation of caveolin
mRNA was also inhibited (Fig. 1D, columns 4 and 5).
Sterols have previously been demonstrated to regu-
late the transcription of a number of genes important
in cholesterol metabolism via the activation of sterol
regulatory element binding proteins (SREBP) (33). We
therefore examined the effect of 25-hydroxycholesterol
(25-OHC), the most potent of SREBP activators (34),
on caveolin mRNA expression. In Fig. 1A, column 2, it
can be seen that addition of 25-OHC (0.5 
 
m
 
g/ml) and
cholesterol (10 
 
m
 
g/ml) to the complete medium for 3
Fig. 1. Caveolin expression in MDCK cells with decreasing cel-
lular cholesterol. MDCK cells were incubated for 3 days in
DMEM containing 10% human serum (complete medium, lane
1), complete medium containing 0.5 mg/ml 25-hydroxy-
cholestero1 (lane 2), LPDS-DMEM containing 25 mm simvastatin
(lane 3), overnight treatment in complete medium containing 1
mg/ml b-trimethyl cyclodextrin (lane 4), or overnight treatment
in LPDS-DMEM containing 1 mg/ml b-trimethyl cyclodextrin
(lane 5). Panel A shows the mean and standard error of total
cell cholesterol measurements from one experiment as percent
of control, panel B a Northern blot with a caveolin I probe, panel
C the same filter as used in panel B with an 18S rRNA probe,
and panel D the quantitated intensity of the caveolin band in
panel B divided by the intensity of the 18S band measured
in panel C.
Fig. 2. Quantitation of caveolin protein in MDCK cells under
cholesterol-lowering conditions by Western blot. Cells were
treated as in Fig. 1, washed in PBS, and solubilized in SDS sample
buffer. Eighty mg of protein was analyzed by SDS PAGE and West-
ern blot. The mean and standard error of three determinations
from one experiment are shown. Similar data were obtained in a
second experiment. Control (column 1), cells grown in DMEM 1
10% human serum; 25-OHC, cells grown in this medium with ad-
dition of 0.5 mg/ml 25-hydroxycholestero1 and 10 mg/ml choles-
terol for 3 days; simvastatin, cells grown in LPDS-DMEM contain-
ing 25 mm simvastatin for 3 days; LDL, cells grown in 10% human
serum containing 0.2 mg/ml of purified human LDL. Symbols in-
dicate significance relative to control, *P 5 0.01, †P 5 0.004, .P 5
0.06.
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days decreased total cellular cholesterol to 76% of con-
trol values. Treatment with 25-OHC reduced the caveo-
lin expression to 77% of control values (Fig. 1D, col-
umn 2). Thus no effect of 25-OHC, other than via
cellular cholesterol levels, on the steady state level of
caveolin mRNA was detected.
The effect of cholesterol depletion on caveolin pro-
tein expression was determined by Western blot of cell
Fig. 3. Indirect immunofluorescence labeling of caveolin in normal and cholesterol-depleted MDCK
cells. MDCK cells were incubated in DMEM 1 10% human serum (a) or overnight in LPDS-DMEM con-
taining 1 mg/ml b-trimethyl cyclodextrin (b). The cells were then fixed and stained with polyclonal anti-
caveolin antibody and rhodamine anti-rabbit IgG. Exposure times were the same in both panels. Arrows
show surface punctate staining and arrowheads identify perinuclear vesicular structures rich in caveolin
protein before cholesterol depletion. Bar, 10 mm.
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lysates. MDCK cells incubated under control and cho-
lesterol-lowering conditions were washed in PBS, lysed
in SDS PAGE sample buffer, and equal amounts of pro-
tein were loaded onto a 12% SDS gel. After Western
transfer and immunoblot with a polyclonal antiserum,
the 22 kD caveolin band was quantitated by densitomet-
ric scanning of the film. In 
 
Fig. 2
 
 it can be seen that
treatment with simvastatin in LPDS-DMEM medium for
3 days caused a 58% decrease in the expression of cave-
olin protein (Fig. 2, column 4). Despite the short treat-
ment time, CD also caused a significant decrease in ca-
veolin protein levels, to 51% of control levels after an
overnight incubation (Fig. 2, column 3). 25-OHC had
no detectable effect on caveolin protein expression
in this experiment. Thus, decreasing the cellular cho-
lesterol, using either simvastatin or CD, caused a sig-
nificant decrease in both caveolin mRNA and protein
levels. In order to study the effect of increased choles-
terol on caveolin expression, we incubated cells in 10%
human serum with the addition of 0.2 mg/ml of puri-
fied human LDL (Fig. 2, column 5). The cellular cho-
lesterol increased only 9% under this treatment and
gave a small increase in caveolin concentration (23%,
 
P
 
 
 
5
 
 0.06).
Caveolin has been reported at two intracellular
locations, in cholesterol-rich domains found in the
Golgi and in caveolae at the cell surface. Indirect im-
munofluorescence staining of MDCK cells grown in
Fig. 4
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medium containing 10% human serum showed in-
tensely stained vesicular structures in a perinuclear re-
gion and a punctate distribution at the cell surface
(Fig. 3A). After overnight treatment in LPDS-DMEM
containing 1 mg/ml CD, both these patterns of fluo-
rescence were severely attenuated (Fig. 3b). No stain-
ing was observed in the absence of the polyclonal anti-
caveolin antiserum (data not shown). This confirms
the result by Western blot and shows that the decrease
in caveolin concentration is caused by the down-
regulation of caveolin protein within each cell. It ap-
pears that both surface and intracellular pools of cave-
olin are affected after an overnight treatment in CD
medium.
Cells treated under cholesterol-depleting conditions
were also examined by electron microscopy. Control
cells (Fig. 4a) showed abundant basolateral invaginated
caveolae. In contrast, after treatment with CD over-
night (Fig. 4b) no invaginated caveolae remained, de-
spite an otherwise normal morphology of the cells. A
similar loss of invaginated caveolae was observed after
cholesterol depletion using simvastatin in LPDS-DMEM
medium. This enabled us to investigate the reappear-
ance of caveolae as cells survive this condition well. Af-
ter 3 days treatment with 25 mm simvastatin in LPDS-
DMEM, a high concentration of mevalonate (2 mm)
was added to the medium, bypassing the block in
HMG-CoA synthesis, and allowing the cells to synthe-
Fig. 4. Loss of caveolae in cholesterol-depleted MDCK cells. MDCK cells grown to confluency were fixed without treatment (a), or
treated with CD overnight in lipoprotein-depleted serum before being fixed (b). Control cells (a) show numerous invaginations mainly
on the basolateral surface (arrowheads) with the typical bulb-shape (shown at higher magnification in the inset) and characteristic size of
caveolae. In contrast, cells treated with cyclodextrin (b) show no recognizable caveolae. However, the general cell morphology is very sim-
ilar to control cells. N, nucleus; L, lateral membrane; A, apical surface. Bars, 200 nm.
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size cholesterol. At times from 1 to 24 h we analyzed to-
tal cellular cholesterol (Fig. 5A), and the number of in-
vaginated caveolae by a quantitative ultrastructural
analysis (Fig. 5B). After simvastatin treatment, no in-
vaginated caveolae were visible in the cells, as before.
Invaginated caveolae first became visible after 4 h in 2
mm mevalonate, and increased in number until, at 24
h, approximately 22% of the number of caveolae seen
in normal cells were observed. These caveolae showed
the typical morphology of caveolae in control cells. In a
separate experiment we measured the expression of ca-
veolin as cells recovered from cholesterol depletion
(Fig. 6). In this experiment the cholesterol levels recov-
ered with kinetics similar to Fig. 5. Caveolin expression
lagged slightly behind the rise in cholesterol concentra-
tion, reaching 60% of normal values at the 24 h time
point.
The lack of morphologically identifiable caveolae in
cells expressing 40–50% of normal caveolin levels sug-
gested a threshold effect of cholesterol levels on caveo-
lae number. To further investigate this, we devised an
experiment in which cells grown in normal medium
were transferred to LPDS-DMEM containing 25 mm
simvastatin and different amounts (0, 20, 200, or 2000
mm) of mevalonate for 3 days. This resulted in steady
state levels of total cellular cholesterol ranging from
54% of control values (no mevalonate added) to 70%
of control values (2000 mm mevalonate added). As pre-
viously determined, the number of caveolae in choles-
terol-depleted cells with no mevalonate added was low
(10% of control in this experiment) and increased to
control values after the cellular cholesterol reached
66% of control values (Fig. 7A). When data from other
experiments, where normal or depleted cholesterol was
at steady state, were plotted on this graph, the same
Fig. 5. Caveolae formation in response to cholesterol synthesis
in cholesterol-depleted MDCK cells. MDCK cells were treated for
3 days in LPDS-DMEM containing 25 mm simvastatin. Mevalonate
(2 mm) was then added for the times shown and cells were ana-
lyzed for cholesterol (panel A) and the number of caveolae by
quantitative electron microscopy (panel B). The cellular choles-
terol in control cells (100%) was 11.8 mg/mg protein in this
experiment.
Fig. 6. Caveolin expression in response to cholesterol synthesis
in cholesterol-depleted MDCK cells. MDCK cells were depleted of
cholesterol for 3 days as in Fig. 5. Mevalonate (2 mm) was then
added for the times shown and cells were analyzed for cholesterol
(panel A) and the expression of caveolin protein (panel B). The
cellular cholesterol in control cells (100%) was 9.9 mg/mg pro-
tein in this experiment.
 at Univ of Queensland (CAUL), on September 29, 2015
w
w
w
.jlr.org
D
ow
nloaded from
 
Hailstones et al. Regulation of caveolin expression 377
threshold effect was observed. Each data point is the re-
sult of counting over 50 cell profiles, carried out with-
out knowledge of the sample history. In a separate exper-
iment we measured the amount of caveolin expressed
under similar conditions (Fig 7B). Unlike the number
of caveolae, the expression of caveolin showed an ap-
proximately linear relationship with the cellular choles-
terol concentration.
DISCUSSION
Caveolin is a cholesterol-binding protein found asso-
ciated with cholesterol-rich domains of the cell surface
and Golgi complex (35). Recently it has been shown
that sterol flux, both out of cells after synthesis in the
endoplasmic reticulum and into cells after exchange
with exogenously added lipoproteins, occurs with con-
comitant accumulation in surface caveolae (25, 36).
Thus caveolin and caveolae might have an important
role in maintaining cellular cholesterol homeostasis. At
the time this manuscript was submitted for publication
another report of caveolin mRNA regulation using fi-
broblasts was published (37). In this report Fielding,
Bist, and Fielding (37) demonstrated that caveolin
mRNA was regulated in parallel with free cholesterol
efflux, and that efflux of cholesterol was proportional
to the amount of oxidizable cholesterol in intact cells,
which was taken as a measure of free cholesterol in ca-
veolae. We have independently tested the relationship
between caveolin expression, cellular cholesterol con-
centration, and the number of caveolae.
In agreement with Fielding et al. (37) we find that ca-
veolin mRNA levels can be regulated under conditions
where the cellular cholesterol level is varied. Unlike
Fielding et al. (37) however, we chose conditions where
no extracellular lipoproteins were present in the me-
dium and cholesterol concentrations were modulated
by the addition of inhibitors of cholesterol synthesis,
cholesterol chelating drugs, and mevalonate. This al-
lowed a greater variation in cellular cholesterol concen-
tration to be achieved. Our data show that caveolin pro-
tein concentration can be regulated over a 2- to 3-fold
range in the same direction as the cellular cholesterol
concentration, giving rise to an approximately linear
relationship. Small changes were observed with the ad-
dition of excess LDL to 10% human serum, suggesting
that caveolin concentrations are likely to be regulated
by cholesterol in vivo. It should be noted that caveolin
is regulated by cholesterol in the opposite direction to
that of the HMG-CoA reductase, cholesterol synthetase,
and the LDL receptor (33), which are all up-regulated
after cholesterol depletion. Indeed, 25-hydroxycholes-
terol, the most potent activator of the sterol regulatory
element binding protein (34), had only a small effect
on caveolin mRNA levels and no detectable effect on
caveolin protein expression. The fact that caveolin pro-
tein is regulated in the absence of lipoproteins in the
medium suggests that the mechanism of regulation is
more likely to be triggered by cellular cholesterol than
by the rate of cholesterol influx, as suggested by Field-
ing et al. (37).
Although caveolin mRNA and protein levels fell rap-
idly after cholesterol depletion, the recovery after addi-
tion of 2 mm mevalonate to the medium was slower, giv-
ing a 22% increase in the numbers of caveolae over 24
h. In parallel experiments, cholesterol and caveolin
concentrations rose to approximately 80% and 60%,
Fig. 7. Caveolae are formed above a threshold in cholesterol
concentration. MDCK cells were treated for 3 days in LPDS-
DMEM containing 25 mm simvastatin and different concentra-
tions of mevalonate to obtain different steady state concentrations
of cholesterol. A: Cells were then fixed for quantitation of caveo-
lae in the electron microscope and extracted for measurement of
total cholesterol. Data from other experiments in which steady
state conditions prevailed are also plotted. B: An experiment car-
ried out as in A in which caveolin protein was measured by quanti-
tative Western blot. The cellular cholesterol in control cells
(100%) was 11.8 mg/mg protein in panel A and 14.0 in panel B.
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respectively, in this time. Thus caveolae formation is
likely to be dependent on sufficient concentrations of
both cholesterol and caveolin protein in the cell as pre-
viously reported (12, 13).
As caveolin is a cholesterol-binding protein, one pos-
sible function of increasing caveolin expression under
conditions of high cholesterol in the cell would be to
provide a ‘sink’ for excess cholesterol in the mem-
brane. Excess plasma membrane cholesterol could be
sequestered in caveolae by caveolin and released from
the cell to extracellular carriers (25, 37). Conversely,
when the cells are depleted of cholesterol, the lower ex-
pression of caveolin decreases the number of caveolae,
and would be expected therefore to decrease the efflux
of cholesterol from the cell. We have shown that deplet-
ing MDCK cells of approximately half of their choles-
terol and caveolin protein caused total ablation of mor-
phologically recognizable caveolae without affecting
cell viability or general morphology. This suggests that
a threshold concentration of caveolin and cholesterol
is required for these structures to form, consistent with
a function of caveolae as a ‘sink’ for excess cholesterol
or as an organelle functioning in the export of excess
cholesterol. A similar phenomenon was observed by
Fra et al. (12) when caveolin cDNA was expressed in
lymphocytes, cells that normally do not express caveo-
lin. In lymphocytes expressing high levels of caveolin,
clusters of small uniformly sized vesicles were observed
beneath the plasma membrane that were labeled by im-
muno-gold labeling with an antibody against caveolin.
In contrast, in cells expressing low levels of caveolin, la-
beling was dispersed over the plasma membrane with-
out the formation of caveolae-like profiles (12). As
caveolin polymers have been suggested to form the stri-
ated coat around caveolae (15), it is plausible that the
formation of invaginated caveolae would be highly de-
pendent on caveolin concentration.
Another consequence of increased numbers of cave-
olae might be an increase in caveolae-mediated uptake
of ligands into the cell. In endothelial cells, where cave-
olae have been shown to mediate lipoprotein move-
ment into the arterial intima (21), elevated levels of cir-
culating lipoprotein have been shown to increase the
transcellular transport of LDL (38). In this case choles-
terol exchanging into the endothelial cell from the cir-
culating lipoproteins might stimulate transcytosis via
increased cellular caveolin concentration and increased
numbers of caveolae. Thus the atherogenic risk associ-
ated with increased transport of lipoproteins across en-
dothelial cells into the arterial intima (39) might, in
part, be due to the effects of cholesterol on caveolin
expression.
In conclusion, our results, in conjunction with those
recently published by Fielding et al. (25, 37), suggest
that caveolin expression regulated by cellular choles-
terol level might regulate the number of caveolae per
cell and hence cholesterol export. As such it could rep-
resent an alternative method for cholesterol homeosta-
sis in cells.
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